Bayer is easing into the cell therapy space through the opening of its first dedicated manufacturing facility in Berkeley, CA, to support later-stage clinical trials and potentially beyond.
The first asset to be developed at the $250 million facility is Bayer-owned BlueRock Therapeutics’ Phase II-ready Parkinson’s…
Click here to view original post
